Female Infertility Pipeline Guide, H1 2020

News provided by

Apr 22, 2020, 17:15 ET

DUBLIN, April 22, 2020 /PRNewswire/ -- The "Female Infertility Pipeline Guide, H1 2020" has been added to ResearchAndMarkets.com's offering.

This Pharmaceutical and Healthcare pipeline guide provides comprehensive information on the therapeutics under development for Women Infertility (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Women Infertility (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Women Infertility and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 9, 19, 15, 1, 26, 8 and 2 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 6 and 3 molecules, respectively.

Women Infertility (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Women Infertility (Women's Health).
The pipeline guide reviews pipeline therapeutics for Women Infertility (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
The pipeline guide reviews key companies involved in Women Infertility (Women's Health) therapeutics and enlists all their major and minor projects.
The pipeline guide evaluates Women Infertility (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
The pipeline guide reviews latest news related to pipeline therapeutics for Women Infertility (Women's Health).

Reasons to Buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
Find and recognize significant and varied types of therapeutics under development for Women Infertility (Women's Health).
Classify potential new clients or partners in the target demographic.
Develop tactical initiatives by understanding the focus areas of leading companies.
Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
Formulate corrective measures for pipeline projects by understanding Women Infertility (Women's Health) pipeline depth and focus of Indication therapeutics.
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Topics Covered

Introduction
Women Infertility - Overview
Women Infertility - Therapeutics Development
Women Infertility - Therapeutics Assessment
Women Infertility - Companies Involved in Therapeutics Development
Women Infertility - Drug Profiles
Women Infertility - Dormant Projects
Women Infertility - Discontinued Products
Women Infertility - Product Development Milestones
Appendix

Companies Mentioned

Adynxx Inc
AlphaMab Co Ltd
Amega Biotech
Aprilbio Co Ltd
Aptorum Group Ltd
ARTham Therapeutics Inc
ASKA Pharmaceutical Co Ltd
Auritec Pharmaceuticals Inc
Bayer AG
Beijing Fogangren Bio-Pharm Tech Co Ltd
Bharat Serums And Vaccines Ltd
Bol Pharma
Cadila Healthcare Ltd
Chugai Pharmaceutical Co Ltd
Context Therapeutics LLC
Daewoong Pharmaceutical Co Ltd
ElexoPharm GmbH
Enteris BioPharma Inc
Eurofarma Laboratorios SA
Evestra Inc
Evotec SE
FemmePharma Global Healthcare Inc
Ferring International Center SA
Forendo Pharma Oy
GeneScience Pharmaceuticals Co Ltd
Genome & Co
Glycotope GmbH
Igenomix SL
Igyxos SA
Immunitor Inc
Isifer AB
Jiangsu Hengrui Medicine Co Ltd
Kissei Pharmaceutical Co Ltd
LG Chem Ltd
Livzon Pharmaceutical Group Co Ltd
Luye Pharma Group Ltd
Mitsubishi Tanabe Pharma Corp
Myovant Sciences Ltd
Navad Life Sciences Pte Ltd
Nippon Shinyaku Co Ltd
NutriBand Inc
Pangen Biotech Inc
Park Active Molecules
Philogen SpA
Predictive Therapeutics LLC
PregLem SA
Richter Gedeon Nyrt
Shanghai Jing Ze Biotechnology Co Ltd
Shenzhen Salubris Pharmaceuticals Co Ltd
SK Chemicals Co Ltd
Suzhou JiSheng Pharmaceutical Co Ltd
SYNG Pharmaceuticals Inc
Takeda Pharmaceutical Co Ltd
Temple Therapeutics BV
TiumBio Co Ltd
Trophogen Inc
Union Therapeutics AS
ValiRx Plc
Viramal Ltd
Xbrane Biopharma AB

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/9n6kdz

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets